2023 World Conference on Lung Cancer (Posters)-EP12.01. Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation

EP12.01. Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation - PDF(Slides)

Back to course

Pdf Summary

This case report discusses the benefits of combining afatinib and osimertinib as a therapeutic option for a female patient with lung adenocarcinoma harboring EGFR19Del/T790M/G724S mutation. The patient initially responded well to gefitinib but experienced disease progression. Next-generation sequencing revealed the emergence of EGFR T790M and G724S mutations alongside the pre-existing EGFR 19del mutation. The patient's treatment regimen was changed to osimertinib, but pleural effusion increased. Afatinib was then added to the treatment, and the patient has continued to receive a combination of afatinib and osimertinib with no observed adverse reactions. The trend of CEA levels indicates a positive response to the combination therapy. This study suggests that combining afatinib and osimertinib could be a viable therapeutic option for patients with lung adenocarcinoma harboring EGFR19Del/T790M/G724S mutation. The study was supported by the Natural Science Foundation of Shaanxi Province and the Health Research Fund Project of Shaanxi Province. The authors acknowledge the contribution of Prof. Zongjuan Ming for providing the chest CT scan of the patient. Increased progression-free survival was achieved with the combination therapy, highlighting its potential effectiveness.

Asset Subtitle

Xin Lyu

Meta Tag

Speaker Xin Lyu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

osimertinib

lung adenocarcinoma

EGFR19Del/T790M/G724S mutation

gefitinib

disease progression

combination therapy

CEA levels

viable therapeutic option

progression-free survival